MedTrace Logo

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

NCT00968851 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 317

Last updated 2014-04-25

No results posted yet for this study

Summary

This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical anti-psychotic therapy. In addition, behavioral and psychotic symptoms will be evaluated.

Conditions

Interventions

DRUG

EVP-6124

Arms: 1

DRUG

Placebo

Arm: 3

DRUG

EVP-6124

Arms: 2

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • FORUM Pharmaceuticals Inc

    lead INDUSTRY

Principal Investigators

  • Chris Southard · Syneos Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-01-31
Completion
2011-03-31

Countries

  • United States
  • Russia
  • Serbia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00968851 on ClinicalTrials.gov